Describe the context and need for advanced training in medical management of CBRN casualties. |
|
|
|
|
|
|
|
Apply the CRESS algorithm to identify toxidromes (consciousness, respirations, eyes, secretions, skin). |
|
|
|
|
|
|
|
Identify opportunities to treat chemical, biological, radiological, and nuclear (CBRN) casualties through the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach. |
|
|
|
|
|
|
|
Recognize useful reference materials for management of CBRN casualties. |
|
|
|
|
|
|
|
Describe nerve agent pathophysiology from molecular to patient level. |
|
|
|
|
|
|
|
Manage nerve agent casualties at the Role 3/4, and intensive care setting. |
|
|
|
|
|
|
|
Recognize novel and contingency treatments for cholinergic crisis. |
|
|
|
|
|
|
|
Integrate NATO-Ally formularies to manage nerve agent casualties. |
|
|
|
|
|
|
|
Prepare for management of multiple simultaneous severe nerve agent casualties. |
|
|
|
|
|
|
|
Describe fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. |
|
|
|
|
|
|
|
Describe the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. |
|
|
|
|
|
|
|
Identify an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. |
|
|
|
|
|
|
|
Select the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. |
|
|
|
|
|
|
|
Describe the importance of and initial formation of the Department of Defense (DoD) and Food and Drug Administration’s (FDA’s) Shelf-Life Extension Program (SLEP). |
|
|
|
|
|
|
|
Summarize eligibility requirements for enrolling medications into SLEP. |
|
|
|
|
|
|
|
Outline chemical treatment considerations for chemical and nerve agent exposures. |
|
|
|
|
|
|
|
Identify inventory considerations and potential use rates when responding to a chemical attack. |
|
|
|
|
|
|
|
Compare USCENTCOM’s informal SLEP program to the DoD’s SLEP program. |
|
|
|
|
|
|
|
Identify the clinical effects and rates of recovery of pulmonary agents and vesicants. |
|
|
|
|
|
|
|
Summarize the pharmacological therapies used to manage patients exposed to pulmonary agents and vesicants. |
|
|
|
|
|
|
|
Given a patient case, select the agent used and appropriate treatment based on exposure history and symptoms. |
|
|
|
|
|
|
|